About

About The GLP-1 Guide

The GLP-1 Guide is a compounded-GLP-1 comparison and education site. We publish transparent rankings, sourced provider data, and clinician-reviewed guides. Here is who runs it, how we work, and the ownership relationship we disclose on every page.

Who publishes this site: The GLP-1 Guide is published by Generation Health, LLC, which is not owned by MaxLife. It is affiliate-supported: we earn referral commissions when readers enroll with providers we feature, including MaxLife — one of the 4 compounded providers ranked here and our current #1. Because of that compensation, we do not present this site as impartial. We compete on transparency: a published rubric, real sourced data, and honest pros and cons for every provider, MaxLife included.

Advertising disclosure: The GLP-1 Guide is published by Generation Health, LLC and is supported by referral commissions. We may earn compensation when you enroll with providers featured here, including MaxLife, our #1-ranked pick. Because of that financial interest, this is not an impartial review; rankings reflect the criteria described on our Methodology page.

Who we are

The GLP-1 Guide is a publication of Generation Health, LLC, which is not owned by MaxLife. We built this site because comparing GLP-1 providers is genuinely hard: pricing is fragmented, most providers do not name their compounding pharmacy, and review counts swing wildly across sources. Our aim is to lay out the field honestly — with our affiliate compensation stated plainly rather than hidden.

Because we earn referral commissions from providers we feature, including MaxLife, we are not a neutral referee, and we do not pretend to be. Instead, we hold ourselves to the same published rubric we apply to every provider, and we show MaxLife's downsides alongside its strengths.

Our affiliate model and how it shapes this site

The GLP-1 Guide is published by Generation Health, LLC and is affiliate-supported. Links to the providers we feature are our own calls to action, and if you start treatment with a provider we feature, including MaxLife, we may earn a referral commission. That is a material connection, and it is why every page carries an advertising disclosure — in the footer, on this page, and next to our rankings.

What that compensation does not do is let MaxLife buy a better score. The rankings follow a fixed, public rubric; where MaxLife loses on a criterion — for example, its review volume of roughly 239 is far smaller than Mochi's ~15,600 or Henry Meds' ~12,500 — the page says so.

Our editorial process

Our rankings come from a single scoring rubric applied identically to every provider, weighted across pricing transparency (25%), pharmacy disclosure (25%), review score and volume (20%), clinical oversight (15%), and support and guarantee (15%). The full method is documented on our Methodology page.

  • Real data only. We publish figures sourced from providers' own pricing pages, public review platforms (Trustpilot, the Better Business Bureau), and reputable third-party reviews. We never invent reviews, ratings, prices, patients, or providers.
  • Sourced and dated. Competitor figures are labeled as sourced in June 2026 and marked "verify live," because provider pricing and review counts change frequently.
  • Placeholders over guesses. Where a value is not confirmed to our standard, we show a visible placeholder instead of filling it in.
  • Refreshed regularly. We aim to re-verify pricing and review data every 30 to 45 days, and each page shows a visible last-updated date.

Our medical-review process

Content that touches medication, efficacy, or safety is reviewed by a licensed medical professional, {{Medical Reviewer Name, Credential}}, whose name and credential appear in the byline of each reviewed page. Medical review checks that clinical statements are accurate, that weight-loss figures are presented as clinical-trial averages rather than promises, and that the not-FDA-approved status of compounded medication is stated wherever the medication is named.

Efficacy framing: In clinical trials combining medication with diet and exercise, average weight loss was ~15% with semaglutide (STEP 1, NEJM 2021) and up to ~24.3% with tirzepatide (SURMOUNT-1, NEJM 2022). These are clinical-trial averages for the FDA-approved drugs; individual results vary and are not guaranteed. This site is for information only and is not medical advice.

What we do not do

We do not present our rankings as impartial — that would be misleading given the referral commissions we earn from providers we feature, including MaxLife. We do not manufacture or compound medication; MaxLife is a telehealth provider, and compounding is performed by its licensed pharmacy partners. We do not publish guarantees of weight-loss results, and we do not run this site as a link farm into other domains.

Corrections and contact

If you find a figure that looks out of date or incorrect, we want to fix it. Provider pricing and review counts move quickly, so we treat corrections seriously and re-verify against the source. You can reach MaxLife, our #1-ranked provider, through maxlife.com.

Publisher & disclosures
Publication:
The GLP-1 Guide (getglp1guide.com)
Published by:
Generation Health, LLC (not owned by MaxLife)
Relationship:
Affiliate-supported; MaxLife is a featured ranked provider (#1)
Impartial?
No — affiliate-supported, not an impartial review
Medical reviewer:
{{Medical Reviewer Name, Credential}}
Rubric:
Published on the Methodology page
Data refresh:
Targeted every 30–45 days
Last updated:
July 3, 2026

Not a manufacturer or compounding pharmacy. Compounding is performed by MaxLife's licensed pharmacy partners. Compounded meds are not FDA-approved. MaxLife is not affiliated with Novo Nordisk or Eli Lilly.